Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET

Company Participants

Neda Safarzadeh - Vice President, Head of Investor Relations, Public Relations & Marketing.

Joe Payne - President & Chief Executive Officer

Andy Sassine - Chief Financial Officer

Pad Chivukula - Chief Scientific Officer & Chief Operating Officer

Conference Call Participants

Evan Wang - Guggenheim Securities

Whitney Ijem - Canaccord Genuity

Myles Minter - William Blair

Jan Hughes - Wells Fargo

Pete Stavropoulos - Cantor Fitzgerald

Thomas Yip - H.C. Wainwright

Yale Jen - Laidlaw and Company

Operator

Greetings and welcome to the Arcturus Therapeutics Fourth Quarter and Full Year 2023 Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Neda Safarzadeh, Vice President, Head of Investor Relations, Public Relations and Marketing. Thank you. You may now begin.

Neda Safarzadeh

Thank you, operator. Good afternoon and welcome to Arcturus Therapeutics’ quarterly financial update and pipeline progress call. Today's call will be led by Joe Payne, our President and CEO; and Andy Sassine, our CFO. Dr. Pad Chivukula, our CSO and COO, will join them for the Q&A session.

Before we begin, I would like to remind everyone that the statements made during this call regarding matters that are not historical facts are forward-looking statements within the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance, and achievements to differ materially from those expressed or implied by the statements. Please see the forward-looking statement disclaimer on the company's press release issued earlier today, as well as the risk factors section in our most recent Form 10-K and in subsequent filings with the SEC.

In addition, any forward-looking statements represent our views only as of the date such statements are made. Arcturus specifically disclaims any obligation to update such statements.

And with that, I will now turn the call over to Joe.

Joe Payne

Thank you, Neda. It's good to be with you again, everybody. We look forward to providing our updates today on our quarterly investor call. I will begin my remarks with an update on progress regarding our Kostaive COVID-19 vaccine program. Following favorable clinical results from several Kostaive studies, including a 16,000 subject efficacy study performed in Vietnam, as well as a Phase 3 COVID-19 booster trial in Japan, the Japan's Ministry of Health, Labor and Welfare, MHLW, granted approval for Kostaive, a self-amplifying mRNA COVID-19 vaccine for primary vaccination and booster for adults 18 years and older.